宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01541 宜明昂科-B

已收盘 08-11 16:08:11

3.500

+0.345

+10.94%

最高3.625	最低3.090	成交量172.62万
今开3.090	昨收3.155	日振幅16.96%
总市值15.02亿	流通市值14.63亿	总股本4.29亿
成交额604.00万	换手率0.41%	流通股本4.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":3.5,"timestamp":1786435691603,"preClose":3.155,"halted":0,"volume":1726200,"delay":0,"changeRate":0.10935023771790815,"floatShares":418000000,"shares":429000000,"eps":-0.53,"marketStatus":"已收盘","change":0.345,"latestTime":"08-11 16:08:11","open":3.09,"high":3.625,"low":3.09,"amount":6040001,"amplitude":0.169572,"askPrice":3.5,"askSize":31200,"bidPrice":3.465,"bidSize":2800,"shortable":0,"etf":0,"ttmEps":-0.589757,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786498200000},"marketStatusCode":5,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":3.155,"openAndCloseTimeList":[[1786411800000,1786420800000],[1786424400000,1786435200000]],"volumeRatio":3.215483,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01541","defaultTab":"news","newsList":[{"id":"2658969219","title":"港股午评|恒生指数早盘跌0.63%    CRO概念继续走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969219","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969219?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:00","pubTimestamp":1786420834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌0.63%，跌163点，报25773点；恒生科技指数跌1.27%。港股早盘成交1158亿港元。药明康德司法取得进展，有利于CXO公司在海外争取新的订单。再鼎医药涨超5%，Q2产品收入环比增长11%，花旗看好中国业务下半年企稳。津上机床中国涨超5%，电子与AI液冷两大领域在新订单占比约四成。黄金股普遍承压。油价走高加剧通胀上行担忧，美联储鹰派释放强硬信号。中国黄金国际跌2.5%；紫金矿业跌3.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348827113.USD","03759","LU1794554557.SGD","LU0326950275.SGD","LU0039217434.USD","BK1170","PONY","LU1720050803.USD","LU0370786039.SGD","SG9999003461.SGD","688062","LU1481107354.HKD","03032","LU0269904917.USD","LU2226246903.HKD","LU1188198961.HKD","02493","LU0348766576.USD","LU1770034418.SGD","07200","LU0048580855.USD","BK1583","LU0828237940.HKD","LU0463099449.HKD","LU0164880469.USD","LU0149721374.USD","LU2460026573.USD","002821","07300","ZLAB","BK1198","LU0348825331.USD","LU1988902786.USD","09115","LU0620787316.HKD","06951","01548","LU1303224171.USD","09088","BK1587","LU0327786744.USD","HK0000320223.HKD","LU2097828714.EUR","513600","BK1183","LU0886674414.USD","LU0266512473.USD","LU1224709979.USD","LU0082770016.USD","HK0000306685.HKD","LU0140636845.USD","LU0540923850.HKD","LU1064131342.USD","BK1191","07552","BK1169","LU0061477393.USD","LU1105468828.SGD","LU0509642566.USD","02833","HSTECH","JINFF","03115","IE0032431581.USD","LU0287142896.SGD","LU0737861699.HKD","LU0634319403.HKD","LU0828237510.HKD","LU2177674079.SGD","LU2039709279.SGD","SG9999002463.SGD","LU0181495838.USD","LU0164939612.USD","LU0345780281.USD","LU0228659784.USD","LU0431992006.USD","LU1769817096.USD","03423","82800","HSI","SG9999001093.SGD","LU0868486357.SGD","LU2097828631.EUR","LU3063872942.SGD","LU0456854461.SGD","LU2264538146.SGD","LU0278937759.USD","BK1190","BK1544","06821","02631","BK1576","LU0328353924.USD","LU0082770016.SGD","LU0244354667.USD","LU2097828474.EUR","LU2488822045.USD","LU0797268264.HKD","HK0000306701.USD","LU1242518931.SGD","HK0000320264.USD","LU2399975544.HKD","02837","LU0106252389.USD","HHImain","LU0417516902.SGD","02800","LU0345780521.USD","LU1808992512.USD","03417","LU0173614495.USD","LU0828238088.HKD","300759","BK1588","688234","LU0348767384.USD","LU0164865239.USD","LU1831875114.USD","LU2008162690.USD","01541","BK1574","BK1505","MCHmain","LU1961090484.USD","09688","LU0307460666.USD","BK1592","LU0348735423.USD","ZIJMY","LU0049853897.USD","LU0274383008.USD","BK1129","01651","02026","LU1769817179.HKD","LU0979878070.USD","03088","LU2097828805.USD","601899","LU0572944931.SGD","LU0531971595.HKD","LU0417516738.SGD","BK1141","LU0043850808.USD","LU0821914370.USD","LU1242518857.USD","LU0588546209.SGD","LU1504937902.USD","LU0329678337.USD","LU1251922891.USD","06616","07500","LU2097828557.USD","LU0918141705.HKD","LU0737861772.HKD","83115","02099","LU0348814723.USD","03419","LU0211977185.USD","LU0348816934.USD","LU0469268626.HKD","LU0329678170.USD","09067","02899","LU1282648689.USD","07226","LU1719994722.HKD","BK1161","BK1594","LU0106959298.USD","LU0096374516.USD","LU1048596156.SGD","LU0165289439.USD","03033","LU0871576103.HKD","LU0918141887.USD","LU0561508036.HKD","03037","LU0266512127.USD","SG9999004220.SGD","300408","03067","BK1109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658966148","title":"港股异动 | 宜明昂科-B(01541)再涨超14% 宜明凯尔首次引入外部商业化资本 加速非肿瘤管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2658966148","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658966148?lang=zh_cn&edition=full","pubTime":"2026-08-11 10:53","pubTimestamp":1786416803,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B再涨超14%，截至发稿，涨10.78%，报3.495港元，成交额313.68万港元。消息面上，宜明昂科发布公告称，附属宜明凯尔与生科起航、新界创元及王雪岩订立增资协议，三名投资者合共以总代价5,000万元人民币，认缴宜明凯尔的46.5万元经扩大注册资本，约占其经扩大股权的15.83%。通过首次引入外部商业化资本，宜明凯尔成功实现了向多元化股权结构的转变，旨在加速其在肺动脉高压等心血管疾病和代谢性疾病领域的创新药研发进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VXUS","KCAI","BK4585","01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658661459","title":"港股异动 | 宜明昂科-B(01541.HK)再涨超14% 宜明凯尔首次引入外部商业化资本 加速非肿瘤管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2658661459","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658661459?lang=zh_cn&edition=full","pubTime":"2026-08-11 10:53","pubTimestamp":1786416803,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657691835","title":"港股异动 | 宜明昂科-B(01541)午后涨近10% 附属宜明凯尔5000万战略增资 加速非肿瘤管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2657691835","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657691835?lang=zh_cn&edition=full","pubTime":"2026-08-07 13:41","pubTimestamp":1786081269,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B(01541)午后涨近10%，截至发稿，涨8.42%，报3.155港元，成交额156.61万港元。消息面上，宜明昂科发布公告称，附属宜明凯尔与生科起航、新界创元及王雪岩订立增资协议，三名投资者合共以总代价5,000万元人民币，认缴宜明凯尔的46.5万元经扩大注册资本，约占其经扩大股权的15.83%。公开资料显示，宜明凯尔专注于肺动脉高压等心血管疾病及代谢疾病领域大分子药物的研发。本次增资旨在进一步充实宜明凯尔的财务资源，加速其在肺动脉高压等心血管疾病及代谢疾病领域的创新药研发进程，标志着宜明昂科“肿瘤+非肿瘤”双轮驱动战略的稳步落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477198.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","VXUS","BK1161","01541","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661971","title":"宜明昂科-B(01541)附属宜明凯尔生物医药技术(上海)获增资5000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661971","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657661971?lang=zh_cn&edition=full","pubTime":"2026-08-07 06:57","pubTimestamp":1786057046,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，于2026年8月6日，本公司、宜明凯尔生物医药技术(上海)有限公司、嘉兴张科领弋生科起航创业投资合伙企业、苏州新界创元企业管理合伙企业及王雪岩先生订立增资协议。根据增资协议，投资者同意以总对价人民币5000万元认缴合共人民币46.5万元经扩大注册资本，约占目标公司经扩大股权的15.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK4588","BK4585","BK4581","XBI","399441","161726","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129045886","title":"宜明昂科-B2026年7月股份变动月报：回购580,000股H股，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1129045886","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129045886?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:41","pubTimestamp":1786005709,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年8月6日发布2026年7月股份变动月报。本月报显示，公司于截止2026年7月31日的注册股本总额为人民币431,507,695元，其中H股注册股本数为420,477,305股，非上市股份注册股本数为11,030,390股。股份变动方面，本月内未有新增发行；公司购回H股580,000股，并将其列作库藏股份。截至本月底，公司H股已发行股份由上月底的419,035,505股调整至418,455,505股，库藏股份由1,441,800股增至2,021,800股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129405823","title":"宜明昂科-B（01541）披露增资视作出售补充信息　完善员工激励平台股权架构","url":"https://stock-news.laohu8.com/highlight/detail?id=1129405823","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129405823?lang=zh_cn&edition=full","pubTime":"2026-07-31 20:20","pubTimestamp":1785500446,"startTime":"0","endTime":"0","summary":"2026年7月31日，宜明昂科生物医药技术（上海）股份有限公司发布补充公告，就2026年6月18日公布的附属公司增资事宜，进一步披露目标公司背景、增资目的及最新股权结构等信息。增资事项已获董事会批准。田博士已申报相关利益并回避表决，董事会认为本次增资定价公平合理，符合公司及股东整体利益。公司确认员工持股平台为独立第三方。公司提醒投资者，买卖公司证券需审慎行事。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174294417","title":"宜明昂科-B回购58,200股股份，总额约18.82万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174294417","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174294417?lang=zh_cn&edition=full","pubTime":"2026-07-24 19:05","pubTimestamp":1784891155,"startTime":"0","endTime":"0","summary":"宜明昂科-B于2026年7月24日发布公告，披露公司于香港联交所场内购回58,200股H股，约占购回前已发行股本的0.0139%。此次回购的价格区间介乎每股港币3.17元至3.31元，合计耗资约18.82万港元。回购完成后，公司普通股已发行股份总数仍为420,477,305股，其中已发行股份为418,455,505股，库存股份变动后增至2,021,800股。截至本公告日，公司已根据上述授权在本交易所或其他证券交易所回购股份合计2,021,800股，涉及已发行股本占比为0.469%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B回购58,200股股份，总额约18.82万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653089506","title":"宜明昂科-B(01541.HK)7月24日斥资18.82万港元回购5.82万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653089506","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653089506?lang=zh_cn&edition=full","pubTime":"2026-07-24 19:01","pubTimestamp":1784890906,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121993486","title":"宜明昂科-B：7月23日回购4.90万股，耗资约16.59万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121993486","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121993486?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:31","pubTimestamp":1784802714,"startTime":"0","endTime":"0","summary":"2026年7月23日，宜明昂科生物医药技术（上海）股份有限公司发布公告，披露当日于香港联合交易所有限公司场内回购普通股H股4.90万股，占回购前公司现有已发行股份总数约0.0117%。本次回购价格区间为每股3.37港元至3.40港元，支付总金额为165,880港元。公司购回授权于2026年5月28日获通过，可回购股份总数为43,150,769股，截至目前已累计回购1,963,600股，占授权股份总数约0.455%。公司声明已遵守相关上市规则与法律规定，并表示本次回购事宜经董事会正式批准。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B：7月23日回购4.90万股，耗资约16.59万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653074939","title":"宜明昂科-B(01541)7月23日斥资16.59万港元回购4.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653074939","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653074939?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:29","pubTimestamp":1784802543,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年7月23日，该公司斥资16.59万港元回购4.9万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158996186","title":"宜明昂科-B：7月22日回购6.42万股，耗资约22.09万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158996186","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158996186?lang=zh_cn&edition=full","pubTime":"2026-07-22 17:26","pubTimestamp":1784712393,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年7月22日进行股份回购，涉及64,200股H股，占公司当日已发行股本约0.0153%。回购价格区间为每股3.40港元至3.50港元，合计耗资约22.09万港元。回购完成后，公司已发行股本总数维持在420,477,305股，其中不包括库藏股的部分为418,562,705股，库藏股数升至1,914,600股。公司确认已遵守香港联交所证券上市规则及相关法律法规，公告由执行董事、联席公司秘书关梅签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B：7月22日回购6.42万股，耗资约22.09万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653755268","title":"宜明昂科-B(01541.HK)7月22日斥资约22.09万港元回购6.42万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653755268","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653755268?lang=zh_cn&edition=full","pubTime":"2026-07-22 17:23","pubTimestamp":1784712232,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140553009","title":"宜明昂科-B 7月17日回购6.38万股股份，耗资约22.04万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1140553009","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140553009?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:16","pubTimestamp":1784287017,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年7月17日公告，显示公司当日于香港联交所场内回购H股6.38万股，占当日现有已发行股份约0.0152%。本次回购每股价格介乎港币3.39港元至3.59港元，回购总金额约22.04万港元。截至目前，公司已依据该授权累计在香港联交所或其他证券交易所回购1,850,400股，占授权生效当日已发行股份总数约0.429%。公司确认，本次回购已根据香港联交所证券上市规则及相关法律规定进行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B 7月17日回购6.38万股股份，耗资约22.04万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652843400","title":"宜明昂科-B(01541)7月17日斥资22.04万港元回购6.38万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652843400","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652843400?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:14","pubTimestamp":1784286898,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年7月17日斥资22.04万港元回购6.38万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651195643","title":"【券商聚焦】国元国际予宜明昂科-B(01541)买入评级 指核心产品临床数据优秀","url":"https://stock-news.laohu8.com/highlight/detail?id=2651195643","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651195643?lang=zh_cn&edition=full","pubTime":"2026-07-13 14:08","pubTimestamp":1783922892,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国元证券经纪 发布研报指，宜明昂科-B核心产品IMM0306在2026年欧洲抗风湿病联盟年会上公布的治疗系统性红斑狼疮的Ib期临床数据优秀，研究达到主要终点。报告强调，公司是CD47靶点开发的全球创新引领者，其CD47融合蛋白IMM01已完成超过300例患者的临床试验，安全性与疗效良好。CD47CD20双抗临床数据优秀，有望成为自免领域重磅药物，CD47三期顺利推进中。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985706","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651328160","title":"国元国际：首予宜明昂科-B(01541)“买入”评级 目标价6.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651328160","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651328160?lang=zh_cn&edition=full","pubTime":"2026-07-13 10:46","pubTimestamp":1783910796,"startTime":"0","endTime":"0","summary":"预计宜明昂科-B2026至2028年实现收入0.32/2.62/4.82亿元人民币。根据DCF模型计算，得出目标市值是27.11亿港元，目标价6.28港元，给予“买入”评级，较现价有83%的升幅。即便考虑开放标签设计对应答率的放大效应，IMM0306的绝对疗效水平仍位于SLE在研管线前列。无严重感染事件与IgG维持正常一致，为长期用药提供了安全窗口。目前公司的CD47融合蛋白总共做了超过300例患者的临床试验，疗效及安全性良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650901520","title":"宜明昂科-B(01541.HK)：IMM0306治疗IgG4相关疾病的II/III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2650901520","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650901520?lang=zh_cn&edition=full","pubTime":"2026-07-10 12:34","pubTimestamp":1783658046,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650015739","title":"宜明昂科-B(01541)：IMM0306治疗IgG4相关疾病的II/III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2650015739","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650015739?lang=zh_cn&edition=full","pubTime":"2026-07-10 12:34","pubTimestamp":1783658046,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，IMM0306 治 疗IgG4 相关疾病 的II/III期试验顺利完成首例患者给药。在严重情况下，该疾病可能导致器官衰竭。现有免疫抑制治疗仍受限于低反应率及高复发率。研究显示，B细胞异常活化及IgG4阳性浆细胞浸润是IgG4-RD的核心病理机制，这与IMM0306的作用机制高度匹配。II/III期临床试验旨在评估IMM0306在降低IgG4-RD患者疾病复发风险方面的疗效，并以此作为其主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1161","III","01541","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197755592","title":"宜明昂科-B：7月9日回购63,600股，耗资约22.16万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197755592","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197755592?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:51","pubTimestamp":1783594274,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年7月9日发布翌日披露报表，公告显示公司当日于香港联交所场内回购H股63,600股，占回购前已发行股本约0.0152%。每股价格介乎3.43港元至3.53港元，合计付出221,570港元。公司于2026年5月28日获股东大会批准可回购股份总数为43,150,769股，迄今为止已于香港联交所及其他交易所累计回购1,786,600股，占授权通过当日已发行股本总数约0.414%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B：7月9日回购63,600股，耗资约22.16万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://immuneonco.com","stockEarnings":[{"period":"1week","weight":0.0194},{"period":"1month","weight":-0.0882},{"period":"3month","weight":-0.1805},{"period":"6month","weight":-0.2958},{"period":"1year","weight":-0.7147},{"period":"ytd","weight":-0.4588}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.0729},{"period":"3month","weight":-0.0156},{"period":"6month","weight":-0.0487},{"period":"1year","weight":0.0434},{"period":"ytd","weight":0.012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜明昂科生物医药技术（上海）股份有限公司是一家主要从事开发肿瘤免疫疗法的中国公司。该公司的主要业务包括开发用于系统利用先天性和适应性免疫的生物技术，以及开发下一代肿瘤免疫疗法，免疫疗法主要专注于适应性免疫系统。该公司的核心产品IMM01是创新靶向CD47的分子。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.125053},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.059944},{"month":3,"riseRate":0.666667,"avgChangeRate":-0.036378},{"month":4,"riseRate":0.666667,"avgChangeRate":0.020918},{"month":5,"riseRate":0.333333,"avgChangeRate":0.218025},{"month":6,"riseRate":0.333333,"avgChangeRate":0.064638},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.092027},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.1299},{"month":9,"riseRate":1,"avgChangeRate":0.120529},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.115476},{"month":11,"riseRate":0,"avgChangeRate":-0.146508},{"month":12,"riseRate":0,"avgChangeRate":-0.128943}],"exchange":"SEHK","name":"宜明昂科-B","nameEN":"IMMUNEONCO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宜明昂科-B,01541,宜明昂科-B股票,宜明昂科-B股票老虎,宜明昂科-B股票老虎国际,宜明昂科-B行情,宜明昂科-B股票行情,宜明昂科-B股价,宜明昂科-B股市,宜明昂科-B股票价格,宜明昂科-B股票交易,宜明昂科-B股票购买,宜明昂科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}